TOKYO, JAPAN – April 14, 2011 – Terumo Corporation (Head Office: Shibuya-ku, Tokyo; President: Yutaro Shintaku - hereinafter "Terumo") announced today the completion of the previously announced pending acquisition of CaridianBCT Holding Corp. (Head Office: Colorado, the United States - hereinafter "CaridianBCT").
The acquisition of CaridianBCT is part of Terumo’s core strategy to achieve the long-term growth target revenue of ¥1 trillion by the year 2020 and constitutes a new growth pillar for the company.
The acquisition also positions Terumo’s blood management business as the global leader in the blood bank technology industry with revenues in excess of $830 million. The combined organization will be able to offer blood bank customers a wider range of blood processing technologies as well as continue product portfolio expansion in the adjacent hospital and biotechnology customer segments.
David Perez, the current President and CEO of CaridianBCT, has been named President and CEO of the combined blood management business of CaridianBCT and Terumo. The global headquarters will be located in Colorado, U.S.
“This is an exciting moment for both companies. We are uniting two industry leaders, both strongly focused on customers and patients with similar cultures and value systems. Both organizations share a passion for innovation and a commitment to developing and delivering customer quality and satisfaction,” said Mr. Perez. “Together, we are poised to be the undisputed global industry leader. I believe we have what it takes – great people, an established brand, a strong product portfolio, an expanding customer base, an innovation pipeline and a strong balance sheet.”
The financials of CaridianBCT will be included within both on the balance sheet and profits and losses of Terumo, on consolidated basis, starting with the first quarter of fiscal 2011 (the business year ending March 31, 2012).
CaridianBCT is the leading global provider of innovative technologies and services in automated blood collections, pathogen reduction technologies, whole blood processes and therapeutic apheresis and cell therapy systems. The company serves patients through its commitment “For Better Blood and Better Lives” by developing and commercializing products that serve global customers in the blood banking, therapeutic apheresis and transfusion medicine industries. For more information, visit http://www.caridianbct.com/.
About Terumo Corporation
Terumo Corporation is a premier global medical device company with annual sales of more than 3.4 billion dollars for the fiscal year ending March 31, 2010. Founded in 1921, the company develops, manufactures and distributes world-class medical devices, such as syringes, blood bags and IV solutions. Terumo has the biggest share of the world markets for angiography guide wires and perfusion products and is a leading developer of interventional products, such as catheters and stents. For more information, visit http://www.terumo.com/.
(Notice) Among the information that Terumo discloses, forecasts of financial performance on future projections contain potential risks and uncertainty since these are forecasts on projections made by Terumo based on limited information available at the moment of disclosure. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.
Terumo Corporation: Tetsuya Kumei
General Manager, Corporate Communications/Investor Relations
Lisa Hayes, Vice President of Global Marketing and Corporate Communications
Phone: +1 303.231.4201